Genomic Health, Inc.
GHDX
GHDX was delisted on the 7th of November, 2019.
130 hedge funds and large institutions have $772M invested in Genomic Health, Inc. in 2016 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 51 increasing their positions, 36 reducing their positions, and 12 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
42% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 12
42% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 36
2% more funds holding
Funds holding: 127 → 130 (+3)
4% more capital invested
Capital invested by funds: $741M → $772M (+$31.5M)
98% less call options, than puts
Call options by funds: $6K | Put options by funds: $373K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$7.18M |
| 2 |
GTC
Ghost Tree Capital
New York
|
+$5.31M |
| 3 |
AC
Ascend Capital
Orinda,
California
|
+$1.99M |
| 4 |
CCMH
Cornerstone Capital Management Holdings
New York
|
+$1.98M |
| 5 |
State Farm Mutual Automobile Insurance
Bloomington,
Illinois
|
+$1.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$9M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$5.76M |
| 3 |
CAM
Cortina Asset Management
Milwaukee,
Wisconsin
|
-$5.51M |
| 4 |
VAM
Visium Asset Management
New York
|
-$3.77M |
| 5 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$2.82M |
GHDX Hedge Fund Activity: Q2 2016 in Review
130 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Genomic Health, Inc. (GHDX) for Q2 2016, worth a combined $772M — up 4.2% from $741M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new GHDX positions and 12 closed out — a net gain of 5 holders — while 51 added to existing stakes and 36 trimmed.
The largest buyer was Broadfin Capital, opening a new position worth an estimated $7.18M. The largest seller was Millennium Management, cutting an estimated $9M.
- 130 institutional investors held Genomic Health, Inc. (GHDX) as of Q2 2016, up from 127 in Q1 2016.
- Funds reported $772M of Genomic Health, Inc. stock for Q2 2016, up 4.2% quarter-over-quarter.
- 17 funds opened new Genomic Health, Inc. positions in Q2 2016 and 12 closed out, a net change of +5 holders.
- The largest Genomic Health, Inc. buyer in Q2 2016 was Broadfin Capital, an estimated $7.18M added.
- The largest Genomic Health, Inc. seller in Q2 2016 was Millennium Management, an estimated $9M sold.
Based on aggregated 13F filings for Q2 2016.